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Abstract: Patients with diabetes have a higher incidence of bladder
cancer; however, the association between thiazolidinedione use and
bladder cancer risk has been controversial. We aimed to investigate
whether pioglitazone or rosiglitazone use is associated with bladder
cancer risk in patients with type 2 diabetes mellitus.
This nationwide nested case-control study used data set obtained
from the Korean National Health Insurance Service National Sample
Cohort 2002 to 2013. Among the 47,738 patients with incident diabetes,
85 cases of newly diagnosed bladder cancer and 850 controls (1:10
matched by age, sex, index year, and diabetes diagnosis year) were
recruited. Type 2 diabetes mellitus and bladder cancer were diagnosed
using the International Statistical Classification of Diseases and Related
Health Problems, 10th Revision code.
More cases of bladder cancer were diagnosed in men (81.2%), and
the stratified age peaked at 70 to 79 years old. Exclusive rosiglitazone
use raised the incidence of bladder cancer (odds ratio [OR]¼ 3.07, 95%
confidence interval [CI ]¼ 1.48–6.37). The risk of bladder cancer
started to increase after less than 3 months use (OR¼ 3.30, 95%
CI¼ 1.02–10.70) and peaked at 3 to 12 months of rosiglitazone use
(OR¼ 4.48, 95% CI¼ 1.51–13.31). Patients were first exposed to
exclusive rosiglitazone within 1 year (OR¼ 11.74, 95% CI¼ 2.46–
56.12) and those who had consistently used it for 1 year (OR¼ 4.48 95%
CI¼ 1.51–13.31), had higher risks of bladder cancer compared with
nonthiazolidinedione users. Neither pioglitazone use nor exclusive
pioglitazone use were associated with an increased incidence of bladderyuri Kim, MD, Yo , PhD,
PhD, and Eun Seok Kang, MD, PhD
diabetes mellitus. The highest odds of bladder cancer in rosiglitazone
users was seen in those with <1 year of exposure.
(Medicine 95(6):e2786)
Abbreviations: CI = confidence interval, COPD = chronic lower
respiratory disease, ICD-10 = International Statistical Classification
of Diseases and Related Health Problems, 10th Revision, NHIS-
HSC = National Health Insurance Service National Sample Cohort,
NIH = Korean National Health Insurance Service, OR = odds ratio,
PPAR = peroxisome proliferator-activated receptor, T2DM = type 2
diabetes mellitus, TZD = thiazolidinedione.
INTRODUCTION
T he prevalence of type 2 diabetes mellitus (T2DM) hasincreased dramatically worldwide.1 Metformin is recom-
mended as a first-line pharmacologic therapy for T2DM man-
agement,2 however, T2DM is a progressive disease that often
requires a second-line agent, such as thiazolidinedione (TZD).2
Thiazolidinediones are ligands of peroxisome proliferator-acti-
vated receptor (PPAR) gamma, a member of the nuclear
receptor superfamily of transcription factors.3 As PPAR gamma
plays essential roles in improving glucose tolerance and insulin
sensitivity, TZDs are referred as ‘‘insulin sensitizers.’’4,5
Bladder cancer has a higher incidence in subjects with
diabetes,6 but the association between TZD use and bladder
cancer risk remains controversial.7–12 The concern of bladder
cancer risk with TZD was first noticed in the Prospective
Pioglitazone Clinical Trials in Macrovascular Events (PROac-
tive), with 14 cases of bladder cancer in the pioglitazone group
compared with 5 in the placebo group (relative risk 2.83; 95%
confidence interval [CI] 1.02–7.85, P¼0.040).11,12 In
addition, large, observational epidemiological studies con-
ducted in Europe, concluded that pioglitazone was associated
with an increased risk of bladder cancer.7,8 However, others
reported no association between the risk of bladder cancer and
TZD use.9,10 A 10-year epidemiological study conducted by the
University of Pennsylvania and Division of Research at Kaiser
Permanente Northern California was undertaken at the request
of the US Food and Drug Administration as a safety study, and
the authors finally announced that there was no association
between bladder cancer risk and the duration of pioglitazone
use, although an interim report described a slightly increased
risk in patients prescribed pioglitazone for more than 24
months.13,14
Most studies have analyzed data derived from Caucasian
subjects and mainly focused on pioglitazone.6–13,15 It is necess-
ary to evaluate the association between TZDs, including pio-
glitazone and rosiglitazone and bladder cancer in Asiansent study, we analyzed data from the
th Insurance Service (NHI), which is a
y with a nationally representative sample
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of the Korean population conducted by the Korea Centre for
Disease Control and Prevention to regularly assess the health
status of general civilians. Our aim was to investigate the
association between TZD use and the incidence of bladder
cancer in a nested case-control study of the T2DM population.
METHODS
Data Source
We used 2002 to 2013 data from the South Korean National
Health Insurance Service National Sample Cohort (NHIS-
NSC). This is nationwide, representative 2%, stratified, random
sample of a Korean population with a baseline of 1,025,340
subjects in 2002 to a final value of 1,014,730 subjects in 2013. It
contains all inpatient and outpatient medical claims data,
including personal information, prescription drugs, diagnostic
and treatment codes, and primary and secondary diagnosis
codes. Mortality data were provided by the National Statistical
Office in Korea.16 Under universal medical coverage, all
medical claims data are collected by the NHI as a monopolistic
health insurer in Korea. Therefore, all subjects in the NHIS-
NSC were maintained until 2013 except for follow-up loss due
to death or disqualification from the NHI (eg, emigration). The
ethics committee of the Yonsei University College of Medicine
approved this study (4–2015–0579).
Incident Diabetes Cohort
Within the NHIS-NSC, among subjects without any pre-
scribed antidiabetic agent in 2002, we selected patients who
were first prescribed oral antidiabetic agents from 2003 to 2013
so that all study subjects had at least 1 year, in which they were
antidiabetic agent free.7 We further excluded patients whose
first antidiabetic agent was insulin and patients who were <40
years old at the time of first antidiabetic prescription. Finally,
patients with type 1 diabetes mellitus or pre-existing T2DM
patients were excluded. The date of incident diabetic cohort
entry was defined as the date of first antidiabetic agent pre-
scription. The last follow-up date was defined as the date of
bladder cancer diagnosis, death, disqualification from NHI, or
December 31, 2013, whichever occurred. The final incident
diabetic cohort consisted of 47,738 patients.
Case-Control Patient Selection From the Incident
Diabetic Cohort
In this nested case-control study with risk-set sampling (or
incidence-density sampling), control patients were chosen from
those in the incident diabetic cohort who were at risk of
becoming a case at the time they were diagnosed.17 The index
date was defined as the date 1 year before the date of bladder
cancer diagnosis. Case patients were identified using the Inter-
national Statistical Classification of Diseases and Related
Health Problems, 10th Revision (ICD-10).18
Case inclusion criteria were first-time diagnosed bladder
cancer (ICD C67.0-C67.9); at least 1 year of a latent period after
T2DM diagnosis; without prior diagnosis of urinary tract cancer
(kidney, renal pelvis, ureter, or bladder cancer, ICD C64.-C67.)
within 5 years before the date of bladder cancer diagnosis; and
presence of clinical codes for treatment (open surgery, transur-
ethral bladder surgery, chemotherapy, radiation, chemothera-
peutic instillation of bladder), codes for death due to bladder
Han et alcancer, codes for diagnosis (biopsy, bladder tumor antigen test,
cystoscopy), or codes for death within 6 months of bladder
cancer diagnosis. Exclusion criteria were a prior diagnosis of
2 | www.md-journal.comurinary tract cancer within 5 years before bladder cancer
diagnosis. Control patients were randomly selected from the
case risk set at a 1:10 ratio after they were matched on a 5-year
interval age group at both 2002 and the time of T2DM diag-
nosis, sex, and date of T2DM diagnosis within 1 year. For
random selection from the matched risk set, we applied the same
exclusion criteria as that of the case group.
Thiazolidinedione Exposure
For all analysis, prescription information before the index
date was used for the identification of drug use. Rosiglitazone
usewas defined as at least one prescription between cohort entry
and the index date. The same definition of drug use was applied
to all types of drugs including nonantidiabetic drugs. Due to the
absence of case patients who had used both rosiglitazone and
pioglitazone, study patients were classified into 3 categories
of TZD use never used TZDs, exclusive rosiglitazone use,
and nonexclusive rosiglitazone use including exclusive
pioglitazone users.
As a secondary analysis, cumulative exposure and time of
exposure among exclusive rosiglitazone users were examined.
The cumulative duration was defined as the number of days
between the first and last prescription plus the duration of last
prescription up to the index date.7 Due to the absence of case
patients who had used rosiglitazone >24 months, cumulative
duration >12 months was the highest level in its category. The
cumulative rosiglitazone dose was computed by summing the
values of all prescriptions obtained by multiplying the daily
dosage by prescribed days for each prescription. Then, the
cumulative doses of rosiglitazone were categorized into tertiles.
To consider the time of exposure, the time of first exposure to
rosiglitazone was defined as the distance between the date of the
first rosiglitazone prescription and the index date. We separated
the above analyses into 2 distinct TZD uses: rosiglitazone
and pioglitazone.
Statistical Analysis
Characteristics of case and control patients are presented as
numbers with percentages for categorical variables and as
means with standard deviations for continuous variables. Con-
ditional logistic regression was conducted to estimate odds
ratios (ORs) and 95% CIs to assess the association between
rosiglitazone use and the risk of bladder cancer. In addition to
matching variables, we adjusted for urolithiasis and other
urinary tract disease (ICD codes N20.-N23., N3.), renal disease
(ICD codes N03.2-N03.7, N05.2-N05.7, N18., N19., I12.0,
I13.1), alcoholic liver disease and alcohol related metal and
behavioral disorders (ICD codes K70., F10.), chronic lower
respiratory disease except for asthma (ICD codes J40.-J47.,
J47.), congestive heart failure (ICD codes I43., I50., I09.9,
I11.0, I13.0, I13.2, I25.5, I42.0, I42.5-I42.9), Charlson comor-
bidity score calculated excluding diabetes and the comorbid
diseases listed above, other antidiabetic drugs use (metformin,
sulfonylurea, dipeptidyl peptidase [DPP]-IV inhibitor, and insu-
lin), aspirin use, statin use, household income as a continuous
variable (from 0 for medical aid to 10 for the highest income
level), and residential area.19 No information on smoking habits
was collected for the NHIS-NSC; therefore, we assumed that
chronic lower respiratory disease indirectly represented
cigarette smoking. A sensitivity analysis was conducted that
Medicine  Volume 95, Number 6, February 2016excluded patients with a diagnostic code alone, those who died
within 6 months of bladder cancer diagnosis, and those with any
previous cancer history. All covariates were assessed by all
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information prior to the index date. All statistical analyses were
conducted using SAS (Version 9.4, SAS Institute Inc, Cary,
NC). A P value <0.05 was considered statistically significant.
RESULTS
From the original cohort of 47,738 subjects with incident
T2DM, 120 patients with a first-time diagnostic code of bladder
cancer were selected. We further excluded 35 patients who did
not satisfy inclusion criteria. There were 85 final case patients,
and the median follow-up time was 2880 days (Figure 1).
Characteristics of Bladder Cancer Cases and
Matched Controls
Table 1 shows the baseline characteristics of the 85 bladder
cancer case patients and 850 control patients. Matching vari-
ables, including age, sex, and year at T2DM diagnosis were
evenly distributed between case and control patients. Partici-
pants were predominantly men (81.2%) and more than half
(56.5%) were over 60 years old. Compared with the control
group, bladder cancer case group patients had more urolithiasis
and previous cancers excluding urinary tract cancer. Chronic
lower respiratory disease and Charlson comorbidity score were
slightly increased in case group.
Relationship Between Thiazolidinedione Use and
Bladder Cancer
Exclusive rosiglitazone use raised the incidence of bladder
cancer by approximately threefold compared to no use of any
TZD (adjusted OR [AOR] 3.07; 95% CI 1.48–6.37, Table 2).
To evaluate the dose-response relationship between exclusive
rosiglitazone use and the rate of bladder cancer, we stratified
cumulative duration and rosiglitazone dose. The risk of bladder
cancer increased after less than 3 months use (AOR 3.30; 95%
CI 1.02–10.70) and peaked at 3 months to 12 months of
Medicine  Volume 95, Number 6, February 2016exclusive rosiglitazone use (AOR 4.48; 95% CI 1.51–13.31).
For those who used the drug more than 12 months, the risk was
relatively lower compared to shorter time period. Similar
Patients who were prescribed any antidiabetic ag
Patients who were newly prescribed antidiabetic
Excluded (n=5,812):
Insulin prescription as 
<40 years of age at the
prescription (n=4,672)
Cohort with incident type 2 diabetes mellitus (n=
Bladder cancer diagnosed (n=120)
Excluded (n=35):
<1 year of latent period
Prior urinary tract canc
No supporting clinical 
Cases of incident bladder cancer (n=85)
FIGURE 1. Flow of subjects through study.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.increased risks were observed in lowest (AOR 3.67; 95% CI
1.24–10.88) and middle tertiles (AOR 4.03; 95% CI 1.25–
12.96) of cumulative rosiglitazone dose. The cumulative dose of
rosiglitazone 4mg tablet once daily for 3 months is 360mg, and
the same dose for 9 months is 1080mg. Therefore, the tertiles of
cumulative dose corresponded to those of cumulative duration.
As for TZD use timing, patients with their first exposure to
exclusive rosiglitazone in 13 to 24 months (AOR 11.74; 95% CI
2.46–56.12) and patients with recent use within 1 year of the
index date (AOR 3.98; 95% CI 1.18–13.41) had higher risk of
bladder cancer. However, neither ever pioglitazone use nor
exclusive pioglitazone use was associated with an increased
incidence of bladder cancer.
Rosiglitazone Use was Independently Associated
With an Increasing Risk of Bladder Cancer
The association between rosiglitazone use and bladder
cancer incidence was evaluated (Supplementary Table 1,
http://links.lww.com/MD/A683). Subjects who had taken rosi-
glitazone at any point had a higher incidence of bladder cancer
(AOR 2.36; 95% CI 1.14–4.87) compared with patients who
had never been exposed to rosiglitazone. The cumulative
duration and doses of rosiglitazone use showed similar patterns
to that observed for exclusive rosiglitazone use. Consistent use
for rosiglitazone less than 12 months and a cumulative dose less
than 2040mg corresponded to 4mg/day for 17 months and,
were associated with higher risks of bladder cancer. However, a
significant increase of bladder cancer incidence was not
observed among subjects who had used pioglitazone for any
time period (Supplementary Table 2, http://links.lww.com/MD/
A683).
Sensitivity Analysis
The results of the sensitivity analysis did not show any
A Nationwide Nested Case-Control Study in Koreadifferences from those of the main analysis. First, after exclud-
ing 13 case patients via diagnostic procedure or test (biopsy,
bladder tumor antigen test, and cystoscopy) and 3 case patients
ents in 2002-2013 (n=77,549)
 agents (n=53,550)
first prescription (n=1,140)




code for incident bladder cancer (n=7)
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TABLE 1. Baseline Characteristics of Bladder Cancer Cases and Matched Controls
Characteristics Cases (n¼ 85), N (%) Controls (n¼ 850), N (%) Crude Odds Ratio (95% CI)
Age at index date, y

40–49 2 (2.4) 23 (2.7) –
50–59 12 (14.1) 123 (14.5) –
60–69 23 (27.1) 237 (27.9) –
70–79 40 (47.1) 386 (45.4) –
80 8 (9.4) 81 (9.5) –
Sex

Male 69 (81.2) 690 (81.2) –
Female 16 (18.8) 160 (18.8) –
Index year, y

2003–2006 57 (67.1) 572 (67.3) –
2007–2009 21 (24.7) 202 (23.8) –
2010–2012 7 (8.2) 76 (8.9) –
Antidiabetes medication use
Metformin 64 (75.3) 593 (69.8) 1.35 (0.79–2.29)
Sulfonylurea 67 (78.8) 707 (83.2) 0.72 (0.40–1.31)
Meglitinide 5 (5.9) 56 (6.6) 0.88 (0.34–2.29)
a-Glucosidase inhibitor 24 (28.2) 214 (25.2) 1.18 (0.71–1.98)
DPP-IV inhibitor 8 (9.4) 56 (6.6) 1.53 (0.67–3.46)
Insulin 4 (4.7) 21 (2.5) 1.96 (0.65–5.89)
Aspirin 22 (25.9) 268 (31.5) 0.74 (0.43–1.25)
Statin 29 (34.1) 313 (36.8) 0.88 (0.54–1.44)
Urolithiasis 23 (27.1) 152 (17.9) 1.75 (1.04–2.97)
History of previous cancer 12 (14.1) 70 (8.2) 1.86 (0.96–3.63)
Renal disease 1 (1.2) 17 (2.0) 0.58 (0.08–4.45)
Alcohol-related disease 4 (4.7) 63 (7.4) 0.69 (0.22–1.74)
Chronic lower respiratory disease 30 (35.3) 256 (30.1) 1.28 (0.79–2.08)
Congestive heart failure 6 (7.1) 78 (9.2) 0.74 (0.31–1.79)
Mean (SD) Charlson comorbidity score 1.74 (1.6) 1.37 (1.4) 1.20 (1.03–1.39)
Mean (SD) household income 5.9 (3.2) 6.5 (3.2) 0.95 (0.89–1.01)
Residential area
Nonmetropolitan 44 (51.8) 462 (54.4) 1.00
Metropolitan 41 (48.2) 388 (45.6) (0.57–1.41)
The index date was defined as the date one year before the date of bladder cancer diagnosis.
tand
Han et al Medicine  Volume 95, Number 6, February 2016due to early death within 6 months after the diagnosis of bladder
cancer, exclusive rosiglitazone use raised the incidence of
bladder cancer by approximately threefold compared with no
use of any TZD (AOR 3.15, 95% CI 1.34–7.37, Supplementary
Table 3, http://links.lww.com/MD/A683). Second, when we
eliminated 17 case patients with any cancer history prior to
the bladder cancer diagnosis, exclusive rosiglitazone use raised
the incidence of bladder cancer by approximately 3-fold com-
pared with no use of any TZD (AOR 5.08; 95% CI 2.09–12.37,
Supplementary Table 4, http://links.lww.com/MD/A683).
Discussion and Conclusions
Recent studies concluded that pioglitazone use was not
associated with a significantly increased risk of bladder can-
cer.10,13 Our group also previously reported no relationship
between pioglitazone use and the incidence of bladder cancer in
Korean patients with diabetes.20 In contrast, research on the
impact of rosiglitazone and bladder cancer risk is limited.
CI¼ confidential interval, DPP-IV¼ dipeptidyl peptidase-IV, SD¼ s
Matching variables.According to a subsidiary analysis included in a pioglitazone
study, rosiglitazone use increased bladder cancer risk in a
statistically insignificant way.7,8 Furthermore, those studies
4 | www.md-journal.comdid not compute the accumulative dose or duration of rosigli-
tazone use. The current study was conducted to identify the
relationship between risk of bladder cancer and TZD use
(pioglitazone and rosiglitazone) in T2DM patients. We used
a nest-control model f, an incident diabetic cohort and found
that rosiglitazone use increased bladder cancer risk. The risk
was higher for subjects who had continuously using rosiglita-
zone for less than 1 year and recent users. However, we found
that pioglitazone use was not related to the risk of bladder
cancer, which is consistent with the above studies.
Patients with diabetes are likely to have a modestly
increased risk of bladder cancer.6 In our study of 47,738
T2DM patients, 120 incident bladder cancer patients were
identified (215 per 100,000 person). This is a higher incidence
than in general populations; the overall rate for bladder cancer
in Korea was 4.6 per 100,000 person in 2011.21 The distribution
of bladder cancer stratified by age peaked at 70 to 79 years old,
which is the same as that of the general Korean populations.21 It
ard deviation.was not known whether there was a difference between bladder
cancer characteristics in T2DM and general population. In
addition, the mechanism underlying bladder cancer in T2DM
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
















Never use of thiazolidinedione 69 (81.2) 752 (88.5) 1.00 (reference) 1.00 (reference)
Ever use of pioglitazone 5 (5.9) 52 (6.1) 1.11 (0.42–2.96) 0.95 (0.34–2.68)
Exclusive pioglitazone 5 (5.9) 40 (4.7) – –
Both rosiglitazone and pioglitazone 0 (0.0) 12 (1.4) – –
Exclusive rosiglitazone 11(12.9) 46 (5.4) 2.57 (1.28–5.17) 3.07 (1.48–6.37)
Cumulative duration of use
Never use of thiazolidinedione 69 (81.2) 752 (88.5) 1.00 (reference) 1.00 (reference)
Ever use of pioglitazone 5 (5.9) 52 (6.1) 1.09 (0.41–2.91) 0.98 (0.35–2.75)
Exclusive rosiglitazone
3 mos 4 (4.7) 14 (1.6) 2.98 (0.96–9.24) 3.30 (1.02–10.70)
3–12 mos 5 (5.9) 14 (1.6) 3.73 (1.32–10.55) 4.48 (1.51–13.31)
>12 mos 2 (2.4) 18 (2.1) 1.21 (0.27–5.39) 1.54 (0.34–7.08)
Cumulative dose of use§
Never use of thiazolidinedione 69 (81.2) 752 (88.5) 1.00 (reference) 1.00 (reference)
Ever use of pioglitazone 5 (5.9) 52 (6.1) 1.09 (0.41–2.91) 0.94 (0.33–2.64)
Exclusive rosiglitazone
356mg 5 (5.9) 14 (1.6) 3.76 (1.33–10.63) 3.67 (1.24–10.88)
357–1080mg 4 (4.7) 15 (1.8) 2.77 (0.91–8.37) 4.03 (1.25–12.96)
>1080mg 2 (2.4) 17 (2.0) 1.27 (0.28–5.78) 1.58 (0.34–7.42)
Time of first use
Never use of thiazolidinedione 69 (81.2) 752 (88.5) 1.00 (reference) 1.00 (reference)
Ever use of pioglitazone 5 (5.9) 52 (6.1) 1.08 (0.40–2.88) 0.93 (0.33–2.63)
Exclusive rosiglitazone
12 mos ago 4 (4.7) 10 (1.2) 4.13 (1.29–13.19) 4.11 (1.22–13.91)
13–24 mos ago 3 (3.5) 6 (0.7) 5.77 (1.35–24.77) 11.74 (2.46–56.12)
>24 mos ago 4 (4.7) 30 (3.5) 1.44 (0.49–4.22) 1.73 (0.58–5.21)
Recency of usey
Never use of thiazolidinedione 69 (81.2) 752 (88.5) 1.00 (reference) 1.00 (reference)
Ever use of pioglitazone 5 (5.9) 52 (6.1) 1.08 (0.40–2.89) 0.94 (0.33–2.65)
Exclusive rosiglitazone
Remote but not recent 5 (5.9) 12 (2.7) 2.33 (0.84–6.45) 3.09 (1.07–8.92)
Recent but not remote 4 (4.7) 10 (1.2) 4.07 (1.27–12.98) 3.98 (1.18–13.41)
Both remote and recent 2 (2.4) 13 (1.5) 1.64 (0.34–7.91) 2.03 (0.41–10.18)
Matched on age group of birth, year at diagnosis of diabetes, and sex. The index date was defined as the date 1 year before the date of bladder cancer
diagnosis.
CI¼ confidential interval.
Adjusted for antidiabetic medication (metformin, sulfonylurea, dipeptidyl peptidase-IV inhibitor, and insulin), aspirin, statin use, past history of
any cancer, renal disease, urolithiasis, other ureter or bladder diseases, congestive heart failure, alcoholic liver disease, Charlson comorbidity score,
household income level, and residential area.
y x d
Medicine  Volume 95, Number 6, February 2016 A Nationwide Nested Case-Control Study in Koreais not clearly understood. The incidence of bladder cancer is
likely to be increased in a high-risk group such as T2DM.22,23
According to a Taiwanese study, older age, male sex, pre-
existing nephropathy, and urolithiasis were associated with
greater bladder cancer risk.22 Renal diseases did not increase
the bladder cancer incidence in our study. However, we also
found more urolithiasis, a well-established form of bladder
tumorigenesis,24 significantly increased bladder cancer risk
(OR 1.75; 95%CI 1.04–2.97). Furthermore, we set latent period
of bladder cancer for 1 year and 3 months to determine whether
Remote exposure was defined as exposure up to 1 year before inde
index date.
§ Categorized into tertiles.rosiglitazone acts as an initiator or promotor. Higher incidence
of bladder cancer for patients with exposure 24 months and
recent rosiglitazone use was observed in both settings. These
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.results implied that rosiglitazone might act as a promoter, which
is in a line with the findings of an in vivo study.25 Given that
T2DM patients might be prone to bladder cancer; rosiglitazone
use might amplify the process in high-risk patients.
Our finding of a high incidence of bladder cancer in
subjects who have used rosiglitazone for less than 1 year is
inconsistent with previous studies that demonstrated a dose-
response relationship of bladder cancer and rosiglitazone
use.23,26 Long-term exposure to rosiglitazone from more than
2 to 5 years was associated with a higher risk of bladder cancer.
ate and recent use was defined as exposure between 1 year before andHowever, the design and settings of previous studies were
different from ours. Patients in the United Kingdom with
pre-existing T2DM who were newly prescribed rosiglitazone
www.md-journal.com | 5
were enrolled in a retrospective cohort study, which is dissim-
ilar to nested case-control study approaches.23 In a Taiwanese
nested case-control study, the index date for cases was defined
as the date of first hospitalization for bladder cancer and included
incident T2DM patients treated with rosiglitazone regardless of
treatment duration.26 No latent period for bladder cancer was
considered in either of those studies. As cancer would not appear
in such a short period, the setting of the latent period for cancer
would be very important and could influence the result. In
addition, no dose–response relationship and the risk peak at less
than 1 year of exposure stays support the hypothesis that rosigli-
tazonemight act as a promoter and have an early effect of bladder
cancer. It is alsopossible that rosiglitazone couldpromote bladder
cancer in subjects with high sensitivity who develop bladder
cancer during the early period of use.
The different effects of pioglitazone and rosiglitazone on
bladder cancer are explained by their effects on PPAR gamma.
Rosiglitazone is considered a pure PPAR gamma agonist,
whereas pioglitazone is both a PPAR alpha and gamma ago-
nist.27 Proliferator-activated receptor alpha controls fatty acid
catabolism, inflammatory response, and homeostasis in liv-
er.28–30 Proliferator-activated receptor gamma regulates adipo-
genesis, insulin action, and plays roles in cell differentiation,
and proliferation.31,32 This disparity could explain the different
effects on lipid metabolism in previous studies.27,33 Moreover,
PPAR gamma mediates the up-regulation of vascular endo-
thelial growth factor, which plays a critical role in tumor
angiogenesis.34 And oxidized low-density lipoprotein stimu-
lates vascular endothelial growth factor expression via PPAR
gamma pathway activation.35 Taken together, the potency of
PPAR gamma agonism exerted by the 2 drugs might result in
different effects regarding bladder cancer.
There are several limitations of this study. First, several
variables that could be associated with bladder cancer inci-
dence, such as smoking, alcohol consumption, obesity, and
exposure to environment and occupational chemicals are not
measured in NHIS-NSC survey. For smoking, a well-known
risk factor for bladder cancer,36 we assumed that chronic lower
respiratory disease indirectly represented smoking cigarettes
and adjusted this in the final risk for bladder cancer. Likewise,
no laboratory tests (glycated hemoglobin, fasting serum glu-
cose, postprandial glucose) of diabetic parameters were avail-
able, so we could not assess whether glycemic fluctuation or
diabetes severity influenced bladder cancer risk. Thiazolidine-
dione is mostly prescribed as the second medication for patients
whose T2DM is poorly controlled with metformin, so the
population of current study would not be in the early disease
stage. We matched cases and controls for age, sex, and date of
T2DM diagnosis; therefore, the effect of those variables would
be minimized. Second, as the data source was derived from a
claim dataset, the actual adherence rates of medication are not
reflected. This weak point was already noticed in a similar
previous design.26 In this study, we assumed all medications
prescribed were taken by the study patients and excluded those
who failed to fill 2 or more prescriptions within 6 months. Third,
the number of case patients was relatively small. We made an
effort to improve on the retrospective cohort study by employ-
ing a nested case-control model. In addition, the study popu-
lation was restricted to newly diagnosed T2DM patient; this
allowed us to assess the pure effect of TZDs and let the case
patients have a 1-year latent period of bladder cancer devel-
Han et alopment. Because of these strict criteria, the final number of
cases was smaller. Despite this, the results were statistically
significant.
6 | www.md-journal.comThere are major strengths of the current study. First, the
nationwide database included a large population of incident
T2DM patients and contained both outpatient and inpatient
references, which were not included in a previous study.7
Second, the concept of the current study model is an aggregate
of preceding analyses, so this nested case-control study is more
sophisticated and provides higher accuracy. As described
above, we determined the latent window period for bladder
cancer after the diagnosis of T2DM and applied strict inclusion
and exclusion criteria.
In conclusion, the present study shows that rosiglitazone
but not pioglitazone increased bladder cancer risk in T2DM
patients. In addition, bladder cancer incidence in rosiglitazone
users was higher among those who had been taking the drug for
less than 1 year. This suggests that rosiglitazone might promote
the development of bladder cancer, but long-term studies are
needed to assess the clear causality and mechanisms regarding
rosiglitazone use and bladder cancer risk. Furthermore, it would
be interesting to determine differences of bladder cancer in the
general population and rosiglitazone users. If there is a clear
relationship between rosiglitazone and bladder cancer, a rosi-
glitazone substitute might be prescribed for high-risk
T2DM patients.
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